Financial Performance Highlights

Consolidated Results FY26:

  • Revenue: ₹380.99 crores, representing 140.37% year-on-year growth
  • EBITDA: ₹47.21 crores, representing 33.29% year-on-year growth
  • Profit After Tax (PAT): ₹14.37 crores, representing 45.52% year-on-year growth
  • EBITDA Margin: 12.39%
  • PAT Margin: 3.77%

Consolidated Results Q4FY26:

  • Revenue: ₹197.93 crores, representing 166.65% quarter-on-quarter growth
  • EBITDA: ₹28.97 crores, representing 366.97% quarter-on-quarter growth
  • PAT: ₹13.25 crores, representing 736.04% quarter-on-quarter growth
  • EBITDA Margin: 14.64%
  • PAT Margin: 6.70%

Standalone Results FY26:

  • Revenue: ₹164.99 crores, representing 30.65% year-on-year growth
  • EBITDA: ₹33.32 crores, representing 22.63% year-on-year growth
  • PAT: ₹16.86 crores, representing 63.61% year-on-year growth

Key Business Developments

Acquisition and Integration:

  • Acquired 74.6% controlling stake in Noumed (Australia, New Zealand and Singapore operations) on November 12, 2025
  • Acquisition provides access to 451 product dossiers and established customer relationships in Australian pharmaceutical market
  • Results include full consolidation of Noumed subsidiaries from Q4FY26 onward

Product Pipeline:

  • Added 88 product dossiers in regulated and emerging markets during FY26
  • Noumed added 5 product dossiers with TGA Australia
  • 67 product dossiers in pipeline for commercialization in FY27

CDMO Business Performance:

  • CDMO revenue surged over 250% year-on-year
  • Supported by signing of new long-term contracts

Capital Markets Activity

IPO Completion:

  • Successfully completed IPO in March 2026 with primary fund raise of ₹285 crore
  • Listed on NSE and BSE on April 02, 2026
  • ₹130 crores allocated for capacity expansion, facility upgradation, and new R&D centre establishment

Capital Expenditure Program

The company is executing a ₹440 crore capex program expected to be completed by FY27:

1. India Capacity Expansion: ₹118 crores for capacity expansion and EU-GMP upgradation at India facilities to support complex injectable formulations, CDMO opportunities, and regulated-market exports

2. Australia Greenfield Facility: AUD 53 million (approximately ₹290 crores) for construction of Australia's largest pharmaceutical plant in Adelaide

  • Facility will enable backward integration for long-term CDMO contracts
  • Supported by AUD 20 million grant from Australian Federal Government
  • On track for completion in Q4FY27 (March 2027 quarter)

3. R&D Centre: ₹18 crores for establishment of dedicated R&D centre to accelerate product development and dossier filings

Management Commentary

Mr. Anil KK, Managing Director, commented on the performance:

  • Cited "outstanding year of growth" with strong finish by SAI and subsidiaries
  • Highlighted operating leverage evidence through dramatic profitability improvement
  • Committed to disciplined growth, margin improvement, and delivering sustained shareholder value in FY27 and beyond
  • Emphasized strong IP-led approach with consistent dossier additions
  • Noted excitement about increasing scale of operations and opportunities from capex-led expansion

Financial Guidance

Management provided FY27 targets:

  • Revenue target: ₹750 crores
  • EBITDA margin target: 17%
  • Outlook underpinned by long-term supply agreements, new dossier commercialization, strategic contribution from Noumed Australia, and sustained momentum across exports and CDMO segments